AtriCure (ATRC) reported $123.62 million in revenue for the quarter ended March 2025, representing a year-over-year increase of 13.6%. EPS of -$0.14 for the same period compares to -$0.25 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $123.43 million, representing a surprise of +0.16%. The company delivered an EPS surprise of +44.00%, with the consensus EPS estimate being -$0.25.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how AtriCure performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• United States Revenue- Pain management: $17.27 million compared to the $16.17 million average estimate based on three analysts. The reported number represents a change of +35.6% year over year.
• International Revenue- Pain management: $1.79 million versus $1.92 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +90.9% change.
• United States Revenue- Total: $101.15 million versus the three-analyst average estimate of $100.60 million. The reported number represents a year-over-year change of +12.1%.
• International Revenue- Total: $22.47 million versus the three-analyst average estimate of $22.70 million. The reported number represents a year-over-year change of +20.8%.
• International Revenue- Minimally invasive ablation: $2.01 million versus $2.37 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -4.8% change.
• International Revenue- Appendage management: $9.67 million compared to the $9.60 million average estimate based on three analysts. The reported number represents a change of +26.5% year over year.
• United States Revenue- Open ablation: $33.31 million compared to the $33.41 million average estimate based on three analysts. The reported number represents a change of +13.7% year over year.
• International Revenue- Open ablation: $9 million compared to the $8.81 million average estimate based on three analysts. The reported number represents a change of +13.8% year over year.
• United States Revenue- Minimally invasive ablation: $8.48 million versus $10.82 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -31.2% change.
• United States Revenue- Appendage management: $42.09 million compared to the $40.21 million average estimate based on three analysts. The reported number represents a change of +17.3% year over year.

View all Key Company Metrics for AtriCure here>>>

Shares of AtriCure have returned +4.4% over the past month versus the Zacks S&P 500 composite's -0.8% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

AtriCure, Inc. (ATRC) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research